TScan Therapeutics, Inc. Common Stock (TCRX)

Price$0.98

Growth ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-19.47%

Price vs S&P 500 (4W)-22.06%

VGM Score50.67

Market Capitalization$64.17M

All Metrics

Book Value / Share (Quarterly)$1.61

P/TBV (Annual)2.46x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.64%

Cash Flow / Share (Quarterly)$-2.08

Price vs S&P 500 (YTD)-9.97%

Net Profit Margin (TTM)-1360.61%

EPS (TTM)$-0.96

10-Day Avg Trading Volume0.44M

EPS Excl Extra (TTM)$-0.96

Revenue Growth (5Y)56.78%

EPS (Annual)$-1.00

ROI (Annual)-83.37%

Net Profit Margin (5Y Avg)-1435.40%

Cash / Share (Quarterly)$2.13

Revenue Growth QoQ (YoY)-54.77%

ROA (Last FY)-56.72%

Revenue Growth TTM (YoY)106.65%

EBITD / Share (TTM)$-0.97

ROE (5Y Avg)-62.86%

Operating Margin (TTM)-1408.73%

Cash Flow / Share (Annual)$-2.46

P/B Ratio0.66x

P/B Ratio (Quarterly)0.58x

Net Income / Employee (Annual)$-913,800

EV / Revenue (TTM)-3.42x

ROA (TTM)-50.14%

EPS Incl Extra (Annual)$-1.00

Current Ratio (Annual)8.41x

Quick Ratio (Quarterly)6.41x

3-Month Avg Trading Volume0.75M

52-Week Price Return-41.55%

Revenue / Employee (TTM)$64,300

Tangible BV / Share (Quarterly)$3.53

P/S Ratio (Annual)6.21x

Asset Turnover (Annual)0.05x

52-Week High$2.57

Operating Margin (5Y Avg)-1511.52%

EPS Excl Extra (Annual)$-1.00

CapEx CAGR (5Y)0.78%

26-Week Price Return-11.54%

Quick Ratio (Annual)8.15x

13-Week Price Return-13.11%

Total Debt / Equity (Annual)0.26x

Current Ratio (Quarterly)6.65x

Enterprise Value$-31.23M

Revenue / Share Growth (5Y)11.49%

Asset Turnover (TTM)0.04x

Revenue / Employee (Annual)$72,700

Pretax Margin (Annual)-1256.81%

Cash / Share (Annual)$2.68

3-Month Return Std Dev77.97%

Net Income / Employee (TTM)$-875,400

ROE (Last FY)-105.40%

EPS Basic Excl Extra (Annual)$-1.00

Total Debt / Equity (Quarterly)0.34x

EPS Incl Extra (TTM)$-0.96

ROI (TTM)-74.14%

P/S Ratio (TTM)7.02x

Pretax Margin (5Y Avg)-1435.40%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$4.10

Price vs S&P 500 (52W)-65.92%

Year-to-Date Return-1.81%

5-Day Price Return-2.78%

EPS Normalized (Annual)$-1.00

ROA (5Y Avg)-36.59%

Net Profit Margin (Annual)-1256.81%

Month-to-Date Return-9.08%

Cash Flow / Share (TTM)$-1.74

EBITD / Share (Annual)$-1.02

Operating Margin (Annual)-1315.38%

LT Debt / Equity (Annual)0.26x

ROI (5Y Avg)-52.22%

LT Debt / Equity (Quarterly)0.34x

EPS Basic Excl Extra (TTM)$-0.96

P/TBV (Quarterly)1.45x

P/B Ratio (Annual)0.46x

Pretax Margin (TTM)-1360.61%

Book Value / Share (Annual)$2.16

Price vs S&P 500 (13W)-21.36%

Beta1.09x

Revenue / Share (TTM)$0.07

ROE (TTM)-91.94%

52-Week Low$0.88

gGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.22est. -0.18

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
TCRXTScan Therapeutics, Inc. Common Stock	—	B	D	$0.98
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

TScan Therapeutics is a clinical-stage biotech company developing T cell receptor (TCR)-engineered T cell therapies to treat cancer. Its pipeline includes TSC-100 and TSC-101, liquid tumor candidates designed to eliminate residual leukemia and prevent relapse following hematopoietic stem cell transplantation, plus multiplexed TCR-T candidates for solid tumors.